Novartis | NOVN - Gross Profit On Sales



Novartis reported $11.51B in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
AbbVie USD 9.34B 1.36B Mar/2025
Alcon AG USD 1.39B 5M Jun/2025
Almirall EUR 191.9M 185.49M Mar/2025
Amgen USD 6.17B 624M Jun/2025
AstraZeneca USD 11.98B 637M Jun/2025
Autolus Therapeutics Ltd -3522000 5.45M Jun/2025
Bayer EUR 6.38B 1.74B Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
Fresenius EUR 1.46B 47M Jun/2025
Fresenius Medical Care EUR 1.22B 31M Jun/2025
Galapagos EUR 61.25M 98.68M Mar/2025
Genmab DKK 868M 195M Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
GlaxoSmithKline GBP 5.82B 229M Jun/2025
GRIFOLS EUR 743.8M 49.13M Jun/2025
Hikma Pharmaceutical USD 692M 64M Dec/2024
J&J USD 14.6B 816M Mar/2025
Lonza CHF 1.04B 72M Dec/2024
Merck EUR 3.03B 118M Jun/2025
Merck USD 12.99B 224M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Novartis USD 11.52B 1.27B Jun/2025
Novo Nordisk 64.01B 1.19B Jun/2025
Orion EUR 248.3M 46.5M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Philips EUR 2.01B 162M Jun/2025
Recordati EUR 423.85M 34.92M Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024
Sanofi EUR 7.74B 26M Jun/2025
UCB EUR 2.46B 520M Dec/2024